Pulse Biosciences

117 articles with Pulse Biosciences

• Pulse Biosciences Announces Health Canada Approval for CellFX® System

  6/9/2021

  Pulse Biosciences Announces Health Canada Approval for CellFX ® System - Company to Expand Global Controlled Launch Program with Clinical Aesthetic Experts in Canada.

• Pulse Biosciences to Participate in the Jefferies Healthcare Conference

  5/24/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the Jefferies Virtual Healthcare Conference. Management is scheduled to present at 12:30pm PT on Wednesday, June 2, 2021.

• Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

  5/13/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the podium presentation of four clinical studies of NPS technology at the American Society for Laser Medicine and Surgery (ASLMS) Virtual Annual Meeting taking place on May 15-16, 2021.

• Pulse Biosciences Reports First Quarter 2021 Financial Results

  5/10/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the first quarter of 2021.

• Pulse Biosciences Schedules First Quarter 2021 Financial Results Conference Call for May 10, 2021

  4/26/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the first quarter of 2021 after market close on Monday, May 10, 2021. Company management will host a corresponding conference call beginning at 1:30pm PT.

• Pulse Biosciences to Present Consumer Research on Patient Perceptions of Benign Lesion Clearance at American Academy of Dermatology VMX Meeting 2021

  4/22/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the presentation of an ePoster at the American Academy of Dermatology (AAD) Virtual Annual Meeting taking place on April 23-25, 2021.

• Pulse Biosciences to Participate in Upcoming Investor Conferences - Mar 05, 2021

  3/5/2021

  Pulse Biosciences, Inc., a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ technology, announced plans to participate in two upcoming virtual investor conferences.

• Pulse Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results

  2/22/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the fourth quarter and full year ended December 31, 2020.

• Pulse Biosciences Announces First CellFX Procedures Performed in Europe as Part of Global Controlled Launch

  2/19/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the first CellFX® procedures in the European Union were successfully completed.

• Pulse Biosciences Announces Start of Controlled Launch of the CellFX System®

  2/16/2021

  Pulse Biosciences Announces Start of Controlled Launch of the CellFX System ® - Shipments of First Commercial-Use CellFX Systems to U.S. and European Dermatologists Commence - First Aesthetic Dermatology Patients Treated in the U.S.

• Pulse Biosciences Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for February 22, 2021

  2/12/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year 2020 after market close on Monday, February 22, 2021.

• Pulse Biosciences, Inc. Announces At-The-Market Equity Offering Program

  2/4/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation ™ (NPS ™ ) technology, today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”), under which it may offer and sell shares of its common stock (the “Shares”) having an aggregate offering price of up to $60,000,000

• Pulse Biosciences Announces FDA Clearance for the CellFX® System

  2/3/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced U.S. Food and Drug Administration (FDA) clearance of the CellFX® System for dermatologic procedures requiring ablation and resurfacing of the skin.

• Pulse Biosciences Announces CE Mark Approval for CellFX® System

  1/25/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced Conformité Européene (CE) mark approval for the CellFX® System.

• Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress

  1/12/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced CellFX® System regulatory progress updates

• Pulse Biosciences, Inc. Announces Redemption of Warrants

  1/5/2021

  Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation TM (NPS™) technology, announced today that on December 31, 2020, it delivered a notice of redemption to redeem all of its outstanding warrants (the “Warrants”) to purchase shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), issued on June

• Pulse Biosciences Grant Equity Incentive Awards To New Employees

  12/15/2020

  Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 40,250 shares of Pulse Biosciences common stock to recently hired non-executive employees under the Pulse Bio

• Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference

  12/4/2020

  Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that a scientific update on its non-thermal NPS mechanism will be featured at the upcoming Controversies and Conversations in Lasers & Cosmetic Surgery Symposium.

• Pulse Biosciences to Participate in Upcoming Investor Conferences

  11/11/2020

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in three upcoming virtual investor conferences. Management is scheduled to present at the Stifel Healthcare Conference on Tuesday, November 17, 2020 at 4:00pm ET. Management is scheduled to present at the Stephens Annual Investment Conference on

• Pulse Biosciences Reports Third Quarter 2020 Financial Results

  11/9/2020

  Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the third quarter ended September 30, 2020. Recent Highlights Submitted a 510(k) Premarket Notification application to the U.S. Food and Drug Administration (FDA) for the CellFX ® System seeking to obtain initial clearance for a general